Skip to content
sellModerate cluster of 6

Kevin Lee sold $141k of BCYC

CHIEF EXECUTIVE OFFICER at BICYCLE THERAPEUTICS plc. 21,314 shares at an average of $6.62, traded Jan 2, 2026, filed Jan 6, 2026.

Warning score
51
Value
$141k
21,314 shares
Holdings after
618,996
-3% from before
From 52-week low
+8%
low $6.17, close $6.68
From 52-week high
-56%
high $15.16, as of Jan 2, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $141k at market
    +11
  • Share of holdings sold
    Sold 3.3% of holdings
    0
  • Cluster
    6 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -19.2%, 3m -25.4%, 6m -33.3%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BCYCOct 9, 2026 · close 3.89
Since filing Jan 6, 2026: -40.8%SPY +13.4% · excess -54.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001776938-26-000002, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 2, 2026AGrant or award
Ordinary Shares
+165,000$0.00$0640,310Jan 6, 2026
Jan 2, 2026SOpen-market sale
Ordinary Shares
-10,325$6.80$70k629,985Jan 6, 2026
Jan 5, 2026SOpen-market sale
Ordinary Shares
-10,989$6.46$71k618,996Jan 6, 2026
Jan 2, 2026AGrant or award
Employee Stock Option (right to buy)derivative
+330,000$0.00$0330,000Jan 6, 2026

Related signals

Other insiders at BICYCLE THERAPEUTICS plc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
15Weak
BCYCsell 610b5-1
BICYCLE THERAPEUTICS plc
Jennifer Scott Perry
Chief Operating Officer
$1,339
356 shares
-0%
30Weak
BCYCsell 6
BICYCLE THERAPEUTICS plc
Michael Skynner
CHIEF SCIENTIFIC OFFICER
$8,534
2,445 shares
-2%
45Moderate
BCYCsell 6
BICYCLE THERAPEUTICS plc
Kevin Lee
CHIEF EXECUTIVE OFFICER
$27k
7,805 shares
-1%
37Weak
BCYCsell 6
BICYCLE THERAPEUTICS plc
Travis Alvin Thompson
Chief Financial Officer
$3,381
972 shares
-1%
30Weak
BCYCsell 6
BICYCLE THERAPEUTICS plc
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
$6,319
1,814 shares
-2%
35Weak
BCYCsell 6
BICYCLE THERAPEUTICS plc
Robert Charles Swanton
director
$12k
3,431 shares
-18%
15Weak
BCYCsell 610b5-1
BICYCLE THERAPEUTICS plc
Jennifer Scott Perry
Chief Operating Officer
$5,313
1,500 shares
-2%
30Weak
BCYCsell 5
BICYCLE THERAPEUTICS plc
Michael Skynner
CHIEF SCIENTIFIC OFFICER
$10k
2,391 shares
-1%
46Moderate
BCYCsell 5
BICYCLE THERAPEUTICS plc
Kevin Lee
CHIEF EXECUTIVE OFFICER
$33k
7,642 shares
-1%
37Weak
BCYCsell 5
BICYCLE THERAPEUTICS plc
Travis Alvin Thompson
Chief Financial Officer
$3,945
923 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kevin Lee sold $141k of BCYC | InsiderTell